| Event: Advisory Committee for Reproductive Health Drugs of the FDA review of NDA 22-139, progesterone gel 8% for the proposed indication of "reduction of risk of preterm birth in women with short uterine cervical length regardless of other risk factors in the mid-trimester of pregnancy.” |
01/20/2012
|
TBD by CDER |